Ralliant Corporation $RAL Shares Purchased by Sei Investments Co.

Posted by on Aug 3rd, 2026

Sei Investments Co. grew its holdings in shares of Ralliant Corporation (NYSE:RAL – Free Report) by 193.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 182,342 shares of the company’s stock after buying an additional 120,248 shares during the quarter. Sei Investments Co.’s holdings in Ralliant were worth $7,583,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in RAL. Viking Global Investors LP purchased a new position in shares of Ralliant in the 2nd quarter valued at $257,200,000. State Street Corp acquired a new position in shares of Ralliant during the 2nd quarter valued at $213,096,000. Millennium Management LLC boosted its position in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after purchasing an additional 3,147,660 shares during the period. Norges Bank purchased a new stake in Ralliant during the 4th quarter worth $124,687,000. Finally, Invesco Ltd. increased its holdings in Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock valued at $169,309,000 after purchasing an additional 1,835,128 shares in the last quarter.

Ralliant Price Performance

Shares of NYSE RAL opened at $65.78 on Monday. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The business has a 50 day moving average price of $67.20 and a two-hundred day moving average price of $54.35. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The firm has a market cap of $7.36 billion, a PE ratio of -6.06, a price-to-earnings-growth ratio of 2.69 and a beta of 1.61.

Ralliant (NYSE:RAL – Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Sell-side analysts expect that Ralliant Corporation will post 2.88 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s payout ratio is -1.84%.

Analysts Set New Price Targets

Several research analysts have commented on RAL shares. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Citigroup upped their target price on Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley increased their target price on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Finally, Wall Street Zen raised Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant has an average rating of “Moderate Buy” and an average target price of $75.70.

View Our Latest Stock Analysis on Ralliant

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

  • Positive Sentiment: Quarterly results exceeded expectations: Ralliant reported second-quarter revenue of approximately $568 million, up 13% year over year, and adjusted EPS of $0.68 versus the $0.63 consensus estimate. Adjusted net earnings were $76 million, while net earnings were $57 million. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
  • Positive Sentiment: Full-year and third-quarter outlooks topped consensus: Ralliant guided third-quarter EPS to $0.72-$0.78 and revenue to $570 million-$590 million, above analyst estimates of $0.68 and $556.4 million, respectively. Full-year 2026 adjusted EPS guidance was raised to $2.76-$2.90 from an analyst consensus of $2.65, with revenue expected around $2.25 billion-$2.30 billion. Ralliant forecasts 2026 revenue and productivity savings
  • Positive Sentiment: Cost-reduction efforts could support future margins: Ralliant’s enterprise productivity program is targeting $50 million-$60 million in annualized run-rate savings by 2028, providing a potential boost to earnings and cash flow.
  • Positive Sentiment: Analysts raised targets: Citigroup increased its target to $82 and initiated a “buy” rating, Truist raised its target to $82 while reaffirming “buy,” and RBC lifted its target to $73 while maintaining a “sector perform” rating. These targets imply meaningful upside from the recent trading level. Benzinga analyst actions
  • Neutral Sentiment: Trading volatility increased: RAL experienced a temporary limit-up/limit-down trading pause during the earnings session, signaling elevated short-term volatility rather than a fundamental change in the business.
  • Negative Sentiment: Valuation and execution risks remain: Despite the adjusted earnings beat, investors may continue to focus on Ralliant’s reported profitability, integration or productivity-program execution, and the gap between the stock’s recent price and analyst targets.

About Ralliant

(Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Featured Articles

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL – Free Report).

Institutional Ownership by Quarter for Ralliant (NYSE:RAL)

Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.